Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Annals of Neurology|February 1, 2011
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Clas Malmeström, Markus Axelsson, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 28, 2022
Systemic inflammation and risk of multiple sclerosis - A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|May 18, 2022
Free vitamin D<sub>3</sub> index and vitamin D-binding protein in multiple sclerosis: A presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 6, 2023
Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damageDaniel Jons, Viktor Grut, Tomas Bergström, et al.
Frontiers in Immunology|August 15, 2022
Plasma protein profiling reveals dynamic immunomodulatory changes in multiple sclerosis patients during pregnancyGeorgia Papapavlou Lingehed, Sandra Hellberg, Jesse Huang, et al.
Annals of Neurology|February 15, 2020
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis PatientsPeter Alping, Johan Askling, Joachim Burman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 21, 2014
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experienceJoachim Burman, Ellen Iacobaeus, Anders Svenningsson, et al.
Pageof 6